ライフサイエンスコーパス: acute coronary syndrome

1 presentation (acute coronary syndrome vs non-acute coronary syndrome).

2 astatin, reduces cardiovascular events after acute coronary syndrome.

3 ardiovascular events in 18144 patients after acute coronary syndrome.

4 ncy domains to predict patient risk after an acute coronary syndrome.

5 8% cardiac event rate defined as death or an acute coronary syndrome.

6 presents to the emergency department has an acute coronary syndrome.

7 ay confer benefits during the early phase of acute coronary syndrome.

8 ial key role of PCSK9 antibodies in managing acute coronary syndrome.

9 s' experience of self-managing recovery from acute coronary syndrome.

10 n leukocyte antigen has been associated with acute coronary syndrome.

11 ts presenting to EDs with possible emergency acute coronary syndrome.

12 charge, all patients were living and without acute coronary syndrome.

13 ratification tool in patients with suspected acute coronary syndrome.

14 ary intervention in patients presenting with acute coronary syndrome.

15 with exertional chest pain, which may mimic acute coronary syndrome.

16 statin therapy in patients stabilized after acute coronary syndrome.

17 ely used to evaluate patients with suspected acute coronary syndrome.

18 , reduces cardiovascular events after recent acute coronary syndrome.

19 rdiovascular events (MACE) in the setting of acute coronary syndrome.

20 risk-stratify patients under evaluation for acute coronary syndrome.

21 nd 73.3% were male, and 36.7% presented with acute coronary syndrome.

22 setting of stable coronary artery disease or acute coronary syndromes.

23 re a mainstay of treatment for patients with acute coronary syndromes.

24 diabetes mellitus, and 39.7% presented with acute coronary syndromes.

25 ervention (PCI) for non-ST-segment elevation acute coronary syndromes.

26 ld benefit from urgent revascularization for acute coronary syndromes.

27 es cardiovascular disease outcomes following acute coronary syndromes.

28 formation and is increased in patients with acute coronary syndromes.

29 in the ischemic microvascular environment of acute coronary syndromes.

30 o aspirin was beneficial in the treatment of acute coronary syndromes.

31 c benefit and bleeding risk in patients with acute coronary syndromes.

32 apid lesion progression before most cases of acute coronary syndromes.

33 in patients with type 2 diabetes and recent acute coronary syndromes.

34 a P2Y12 inhibitor has not been assesssed in acute coronary syndromes.

35 nvolved in the pathogenesis of psoriasis and acute coronary syndromes.

36 ving technique, and its use is increasing in acute coronary syndromes.

37 standard antithrombotic treatment following acute coronary syndromes.

38 h consisted of both non-ST-segment elevation acute coronary syndrome (14%) and ST-segment elevation m

39 utcomes Network-Get With The Guidelines) for acute coronary syndromes (182,903 patients admitted to 9

40 ommon in acute coronary syndrome (versus non-acute coronary syndrome; 22% versus 19%), de novo (versu

41 The most common primary diagnosis was acute coronary syndrome (25%), which consisted of both n

42 tions were stable coronary disease (69%) and acute coronary syndromes (31%).

43 ular disease: from bench to beyond-Premature Acute Coronary SYndrome), a prospective observational co

44 Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac trop

45 In women with acute coronary syndrome, a smaller lipid arc (171.6+/-53

46 ntricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased

47 of genetically confirmed FH in patients with acute coronary syndrome (ACS) and compared the diagnosti

48 patients with chronic periodontitis (CP) and acute coronary syndrome (ACS) and establish their correl

49 We examined incidence of depression after acute coronary syndrome (ACS) and whether the timing of

50 Most patients with acute coronary syndrome (ACS) are treated with statins,

51 irst primary endpoint (PEP) in patients post-acute coronary syndrome (ACS) compared to placebo/simvas

52 sessed the incidence of AKI in patients with acute coronary syndrome (ACS) enrolled in the MATRIX-Acc

53 Patients who have had an acute coronary syndrome (ACS) event have an increased ri

54 Although the early outcome of acute coronary syndrome (ACS) has considerably improved

55 artment patients with symptoms suggestive of acute coronary syndrome (ACS) have had mixed success.

56 ng (SPECT-MPI) has high predictive value for acute coronary syndrome (ACS) in emergency department pa

57 ays (hs-troponins) for patients suspected of acute coronary syndrome (ACS) in the emergency departmen

58 Acute coronary syndrome (ACS) is a frequent cause of hos

59 patients undergoing coronary angiography for acute coronary syndrome (ACS) or stable angina, in whom

60 Many low-risk acute coronary syndrome (ACS) patients are not pre-treat

61 asingly used for clinical decision making in acute coronary syndrome (ACS) patients with intermediate

62 an one-third of smokers hospitalized with an acute coronary syndrome (ACS) remain abstinent following

63 ndothelial cells (ECs) or from patients with acute coronary syndrome (ACS) to promote premature EC ag

64 r (CV) outcomes in patients stabilized after acute coronary syndrome (ACS) when added to statin thera

65 Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent des

66 heir role in the prediction of recurrence of acute coronary syndrome (ACS), but the value of genetic

67 Patients with acute coronary syndrome (ACS), especially those receivin

68 Acute coronary syndrome (ACS), the acute manifestation o

69 n era of high-dose statin prescription after acute coronary syndrome (ACS), the risk of recurrent cor

70 sment of Treatment Patterns and Events After Acute Coronary Syndrome (ACS)-Prospective, Open Label, A

71 ) trial, which enrolled 18 624 patients with acute coronary syndrome (ACS).

72 , biological, and clinical outcomes after an acute coronary syndrome (ACS).

73 ute chest pain are ultimately diagnosed with acute coronary syndrome (ACS).

74 department patients with symptoms suggesting acute coronary syndrome (ACS).

75 stent thrombosis, particularly in those with acute coronary syndrome (ACS).

76 y of coronary CTA in patients with suspected acute coronary syndrome (ACS).

77 differences in access to care for premature acute coronary syndrome (ACS); whether they are associat

78 t CAD ( n = 123), stable CAD ( n = 184), and acute coronary syndrome (ACS; n = 169).

79 ation (1B-2C depending on rhythm), status in acute coronary syndromes (ACS) (1C), the presence of per

80 uments, indications for revascularization in acute coronary syndromes (ACS) and stable ischemic heart

81 about the pathophysiology and mechanisms of acute coronary syndromes (ACS) at the clinical, patholog

82 The role of allergic inflammation in acute coronary syndromes (ACS) has not been clearly defi

83 outcomes in medically managed patients with acute coronary syndromes (ACS) is not known.

84 ith stable ischemic heart disease (SIHD) and acute coronary syndromes (ACS) is unknown.

85 lor with or without aspirin in patients with acute coronary syndromes (ACS) undergoing isolated coron

86 response has been observed in patients with acute coronary syndromes (ACS) with reduced expansion of

87 nary artery bypass grafting (CABG) following acute coronary syndromes (ACS).

88 hed as a guide to treatment in patients with acute coronary syndromes (ACS).

89 red with a conservative invasive approach in acute coronary syndromes (ACSs), but the effectiveness o

90 HR, 1.55 [95% CI, 1.31-1.83]; P < .001), and acute coronary syndrome (adjusted HR, 1.53 [95% CI, 1.14

91 ted HR, 1.70 [95% CI, 1.23-2.36]; P = .001), acute coronary syndrome (adjusted HR, 2.03 [95% CI, 1.24

92 mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular

93 Among patients with stable angina or an acute coronary syndrome, an iFR-guided revascularization

94 Prespecified high-risk subgroups included acute coronary syndrome and de novo or graft body lesion

95 a higher rate of cardiac events (such as the acute coronary syndrome and heart failure) than those of

96 therapies treat acquired syndromes, such as acute coronary syndrome and heart failure, which develop

97 the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for furth

98 focus on their application in patients with acute coronary syndrome and in specific lesion subsets (

99 iabetic patients with moderate and high-risk acute coronary syndrome and multivessel disease managed

100 e-scale ACUITY trial, diabetic patients with acute coronary syndrome and multivessel disease treated

101 ation between WBC and MACE was consistent in acute coronary syndrome and non-acute coronary syndrome

102 ith platelet function tests in patients with acute coronary syndrome and platelet activation markers

103 in determining IL-18 levels in patients with acute coronary syndrome and we have identified genetic v

104 s admitted because of symptoms suggesting an acute coronary syndrome and who were entered into a larg

105 nts hospitalised with acute heart failure or acute coronary syndrome and with predicted 12 month mort

106 Patients admitted for acute coronary syndrome and/or revascularization, with >

107 Most patients had non-ST-elevation acute coronary syndromes and complex lesions.

108 y (OR, 1.01; 95% CI, 0.98-1.03; P = .62) for acute coronary syndromes and elective procedures requiri

109 of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percut

110 Given the prominent role of acute coronary syndromes and invasive procedures in card

111 rization strategy for diabetic patients with acute coronary syndromes and multivessel coronary artery

112 abetes mellitus have reduced longevity after acute coronary syndromes and revascularization.

113 of acute cardiovascular diseases, including acute coronary syndromes and stroke; the care of cardiov

114 had claims-identified AMI, 16.5% had non-AMI acute coronary syndrome, and 25.8% had other cardiac cla

115 n for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute panc

116 pathophysiological mechanism that underlies acute coronary syndromes, and therefore, antiplatelet th

117 n Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome]), and sitagliptin (TECOS [Trial

118 rction (HORIZONS-AMI) and European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) trials, we

119 porated into the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial, which assign

120 clinical trial (EUROMAX [European Ambulance Acute Coronary Syndrome Angiography]) included 2198 pati

121 cutaneous Coronary Intervention Presentation-Acute Coronary Syndrome (APTITUDE-ACS) study, patients p

122 Patients who experience an acute coronary syndrome are at heightened risk of recurr

123 g the transition from hospital to home after acute coronary syndrome are less favorable for men and t

124 riteria included diagnosis of ES, absence of acute coronary syndrome as the arrhythmic trigger, and >

125 symptoms and being investigated for possible acute coronary syndrome at hospitals in New Zealand, Aus

126 r risk were female gender, thrombocytopenia, acute coronary syndrome, atrial fibrillation, congestive

127 nt of patients with non-ST-segment elevation acute coronary syndromes awaiting coronary angiography i

128 TTS, however, differs from an acute coronary syndrome because patients have generally

129 gs to patients with non-ST-segment elevation acute coronary syndromes before coronary angiography is

130 d 11% if they were on insulin), and a recent acute coronary syndrome (between 15 and 90 days before r

131 States (77.9% vs 40.0%), and present with an acute coronary syndrome, but they had lower comorbid dis

132 ary end point was death and new or recurrent acute coronary syndrome by 12 months.

133 sis on a case-control cohort comprising 5376 acute coronary syndrome cases and 4852 unrelated control

134 ty and cardiovascular morbidity (such as the acute coronary syndrome, cerebrovascular accidents, and

135 In stabilized individuals within 10 days of acute coronary syndrome, combination therapy seemed to b

136 ore frequently with non-ST segment elevation acute coronary syndrome compared with patients without D

137 e of cardiovascular death, acute MI or other acute coronary syndrome, coronary revascularization, or

138 sment of Treatment Patterns and Events after Acute Coronary Syndrome) data, we examined 6-week and 1-

139 Data about clinical characteristics, acute coronary syndrome diagnosis and treatment, extraco

140 associated with vulnerability to rupture and acute coronary syndromes, emerging evidence also suggest

141 6 141 patients with non-ST-segment-elevation acute coronary syndrome enrolled in 11 phase III clinica

142 All potential acute coronary syndrome episodes were adjudicated in a b

143 (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00

144 Patients with type 2 diabetes and an acute coronary syndrome event in the previous 15-90 days

145 within 10 days after admission for the index acute coronary syndromes event to either aspirin or riva

146 edian follow-up of 4.8 years, there were 225 acute coronary syndrome events, including 141 MIs and 84

147 low percentage of patients hospitalized for acute coronary syndromes filled high-intensity statin pr

148 agement interventions among people following acute coronary syndrome for sustained effect and within

149 We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to

150 tionated Heparin During Revascularization in Acute Coronary Syndromes (FUTURA/OASIS-8) trial, 2026 pa

151 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically

152 zetimibe in addition to statin therapy after acute coronary syndrome has been published.

153 ezetimibe to statin therapy in subjects with acute coronary syndromes has renewed the enthusiasm for

154 h a high likelihood of rupture leading to an acute coronary syndrome, have gained great interest in t

155 rrelates of ST included presentation with an acute coronary syndrome (hazard ratio [HR]=1.81, P=0.01)

156 Pioglitazone reduced the risk of acute coronary syndrome (hazard ratio, 0.71; 95% confide

157 d risk for a cardiovascular event (including acute coronary syndrome, heart failure hospitalization,

158 In suspected acute coronary syndrome, high-sensitivity cardiac tropon

159 0.94; Pinteraction=0.037), presentation with acute coronary syndrome (HR, 0.88; 95% CI, 0.83-0.94; Pi

160 tected when work up is performed to rule out acute coronary syndrome in patients presenting with exer

161 d not reduce 12-month death or new/recurrent acute coronary syndrome in the overall population (hs-re

162 e screening tests who will be diagnosed with acute coronary syndrome in the subsequent 48 hours.

163 I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjud

164 ng adults presenting to the ED with possible acute coronary syndrome in whom an ECG and hs-cTnT measu

165 97 study subjects and the prognostication of acute coronary syndromes in 368 study subjects.

166 cardial infarction, unstable angina, and non-acute coronary syndrome) in The Blue Cross Blue Shield o

167 Non-ST-segment elevation acute coronary syndromes include unstable angina and non

168 oronary artery disease or presenting with an acute coronary syndrome, including ST-segment-elevation

169 Mortality in cardiogenic shock complicating acute coronary syndrome is high, and objective risk stra

170 ary intervention in patients presenting with acute coronary syndrome is independently associated with

171 Acute coronary syndrome is the leading cause of mortalit

172 to statin therapy in patients with a recent acute coronary syndrome leads to reductions in cardiovas

173 versus nonculprit arteries in patients with acute coronary syndrome (median difference: 0.69; interq

174 pioglitazone, in comparison with placebo, on acute coronary syndromes (MI and unstable angina) among

175 Patients with suspected acute coronary syndrome (n=1218) underwent high-sensitiv

176 Patients with cardiogenic shock caused by acute coronary syndrome (n=145).

177 tential for persistent hsTnI elevation after acute coronary syndrome (n=3808).

178 in reason for cardiac catheterization was an acute coronary syndrome (n=54).

179 er stable coronary artery disease (n=320) or acute coronary syndromes (n=115).

180 The total number of PCIs in patients with no acute coronary syndrome/no prior coronary artery bypass

181 nd (3) revascularization not associated with acute coronary syndrome (non-ACS).

182 composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in a myocardial in

183 c death (SCD) after non-ST-segment elevation acute coronary syndrome (NSTE ACS) has not been characte

184 In patients with non-ST-segment-elevation acute coronary syndrome (NSTE ACS), elevated troponin le

185 gy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardi

186 nts presenting with non-ST-segment-elevation acute coronary syndrome (NSTE-ACS).

187 Non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are the leading caus

188 y) in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS).

189 In patients with non-ST-segment elevation acute coronary syndromes, OCT-guided PCI is associated w

190 95% confidence interval, 1.7-3.6) or non-AMI acute coronary syndrome (odds ratio, 2.7; 95% confidence

191 ontribute to superficial erosion, a cause of acute coronary syndrome of likely growing importance in

192 ns, 92 miRNAs were assessed in patients with acute coronary syndrome on different antiplatelet therap

193 alysis, five had grade 4 adverse events (one acute coronary syndrome, one biliary tract infection, on

194 myocardial infarction OR angina pectoris OR acute coronary syndrome OR coronary artery disease OR ca

195 PTITUDE-ACS) study, patients presenting with acute coronary syndrome or for elective percutaneous cor

196 atelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Interve

197 heterization is performed in the work up for acute coronary syndrome or when computed tomography coro

198 present with symptoms indistinguishable from acute coronary syndrome or with electrocardiogram change

199 alone versus dual-antiplatelet therapy after acute coronary syndromes or coronary stent implantation.

200 Is performed in New York in patients without acute coronary syndromes or previous coronary artery byp

201 andomized participants with non-ST-elevation acute coronary syndromes or stable angina and to evaluat

202 openia (OR, 0.79; CI, 0.62-1.00; P = 0.049), acute coronary syndrome (OR, 0.72; CI, 0.58-0.89; P = 0.

203 5% CI, 0.96-1.03; P = .65), non-ST-elevation acute coronary syndrome (OR, 0.99; 95% CI, 0.93-1.05; P

204 hrombotic disorders such as ischemic stroke, acute coronary syndrome, or acute limb ischemia.

205 e and of the composite outcome of stroke, an acute coronary syndrome, or death from cardiovascular ca

206 isease, cancer with or without chemotherapy, acute coronary syndrome, or volume depletion, were at hi

207 nt interventions among individuals following acute coronary syndrome; or (2) patients' experience of

208 sment of Treatment Patterns and Events After Acute Coronary Syndrome) participating hospitals to dete

209 vely analyzed postprocedural OCT findings in acute coronary syndrome patients and explored its possib

210 Among 13 819 moderate and high-risk acute coronary syndrome patients enrolled in the Acute C

211 of short-term mortality and complications in acute coronary syndrome patients treated with extracorpo

212 of short-term mortality and complications of acute coronary syndrome patients treated with extracorpo

213 usion criteria were observational studies on acute coronary syndrome patients treated with extracorpo

214 In this retrospective study of acute coronary syndrome patients undergoing percutaneous

215 Non-ST-segment-elevation acute coronary syndrome patients undergoing percutaneous

216 before operating on P2Y12 inhibitor-treated acute coronary syndrome patients, to allow dissipation o

217 e NLRC4 inflammasome for IL-18 production in acute coronary syndrome patients.

218 ACT and outcomes in non-ST-segment-elevation acute coronary syndrome patients.

219 Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients: NCT01603082).

220 estores platelet reactivity in patients with acute coronary syndrome/percutaneous coronary interventi

221 ac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, significant arrhy

222 cribe the effects of CI-AKI in a large-scale acute coronary syndrome population, and the relationship

223 Troponin in the Evaluation of Patients With Acute Coronary Syndrome) population (<5 ng/L at presenta

224 (eg, treatment of venous thromboembolism or acute coronary syndrome), preference should be given to

225 y diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syn

226 included clinical and angiographic factors (acute coronary syndromes presentation, diabetes mellitus

227 onsistent in acute coronary syndrome and non-acute coronary syndrome presentations (interaction P=0.1

228 awasaki disease is no longer a rare cause of acute coronary syndrome presenting in young adults.

229 nsecutively enrolled patients with suspected acute coronary syndrome presenting to four secondary and

230 Independent predictors of CTEs included acute coronary syndrome, prior revascularization, diabet

231 ces in relation to self-management following acute coronary syndrome provided important insights into

232 m November 2014 to November 2016 through the Acute Coronary Syndrome Quality Improvement in Kerala ra

233 akotsubo cardiomyopathy, as compared with an acute coronary syndrome, rates of neurologic or psychiat

234 to simvastatin in patients stabilized after acute coronary syndrome reduces the frequency of ischemi

235 covering primary care, hospital admissions, acute coronary syndrome registry, and mortality (Cardiov

236 t beyond clinical variables in patients with acute coronary syndrome-related cardiogenic shock and ma

237 f-management interventions among people with acute coronary syndrome remains inconclusive.

238 ecommendations do not apply to patients with acute coronary syndrome, severe thrombocytopenia (patien

239 ion before randomisation), for patients with acute coronary syndromes started within 10 days after pr

240 i) CVD events/deaths (myocardial infarction, acute coronary syndrome, stroke, congestive heart failur

241 tcome (a composite of myocardial infarction, acute coronary syndrome, stroke, heart failure, and CVD

242 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects [TRILOGY ACS]; NCT00699

243 and 1-month post-discharge 1521 nondemented acute coronary syndrome survivors enrolled in TRACE (Tra

244 pproaches to the evaluation and treatment of acute coronary syndromes that are more prevalent in wome

245 n patients with type 2 diabetes and a recent acute coronary syndrome, the addition of lixisenatide to

246 In patients with an acute coronary syndrome, the rates of major adverse card

247 ctice guideline for non-ST-segment-elevation acute coronary syndromes, there is wide variation in the

248 In cases with the risk haplotype for acute coronary syndrome, these results suggest involveme

249 and timely use of thrombolysis and stents in acute coronary syndrome to limit or prevent infarction.

250 ients randomized >/=30 days after qualifying acute coronary syndrome to mitigate the potential for pe

251 g 240 patients with non-ST-segment elevation acute coronary syndromes to compare OCT-guided PCI (use

252 s a commonly used drug in the acute phase of acute coronary syndromes to relieve pain-with the added

253 en shown, in large-scale clinical trials for acute coronary syndromes, to reduce ischaemic events mor

254 r Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) study with at least 1 t

255 r Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER), and Targeted Platelet

256 Heart Attack and Stroke in Participants With Acute Coronary Syndrome [TRACER] [Study P04736]; NCT0052

257 sment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) between April 20

258 sment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study between Ap

259 sment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study from 2010

260 sment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) study.

261 2026 patients with non-ST-segment-elevation acute coronary syndrome treated with fondaparinux 2.5 mg

262 ify the Optimal strateGy to medically manage Acute Coronary Syndromes) trial of aspirin plus prasugre

263 by age in phase III non-ST-segment-elevation acute coronary syndrome trials was unchanged over time.

264 ify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trials.

265 ne in patients with non-ST-segment-elevation acute coronary syndrome undergoing an invasive strategy

266 rospective cohort study of all patients with acute coronary syndrome undergoing PCI from CathPCI Regi

267 trongly associated with AKI in patients with acute coronary syndrome undergoing PCI.

268 culprit lesion OCT findings in patients with acute coronary syndrome undergoing percutaneous coronary

269 ectomies from 111 patients with ST-elevation acute coronary syndrome undergoing primary percutaneous

270 mproves outcomes in unselected patients with acute coronary syndromes undergoing invasive management.

271 of 5 years for MACEs (cardiovascular death, acute coronary syndrome, unscheduled revascularization o

272 age, 75; 23% women) and were more common in acute coronary syndrome (versus non-acute coronary syndr

273 e) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome).

274 2003 estimated that the risk of stroke or an acute coronary syndrome was 12 to 20% during the first 3

275 ost participants in the qualitative studies, acute coronary syndrome was unexpected and the recovery

276 nts admitted with a non-ST-segment elevation acute coronary syndrome, we constructed an ANN that iden

277 study of consecutive patients with suspected acute coronary syndrome, we evaluated the performance of

278 able coronary artery disease or a stabilised acute coronary syndrome were enrolled at 301 academic an

279 because of stable coronary artery disease or acute coronary syndrome were included from the nationwid

280 ent and adopting lifestyle changes following acute coronary syndrome were influenced by subjective li

281 Patients who experienced acute coronary syndrome were randomized to a placebo/sim

282 , 2015, and Oct 14, 2016, 3037 patients with acute coronary syndromes were randomly assigned; 1518 to

283 ,098 unselected all-comer patients (50% with acute coronary syndrome) were randomly assigned to have

284 tients, with or without ST-segment elevation acute coronary syndrome, were randomly assigned to radia

285 clear as to why it might predict the risk of acute coronary syndromes, which are usually due to plaqu

286 f 2037 participants with stable angina or an acute coronary syndrome who had an indication for physio

287 e measured in 125 patients with a history of acute coronary syndrome who had undergone detailed asses

288 ty of patients with non-ST-segment-elevation acute coronary syndrome who underwent an early invasive

289 n all patients with non-ST-segment-elevation acute coronary syndrome who underwent an invasive strate

290 complex to precisely identify risk loci for acute coronary syndrome with effective clinical implicat

291 International Trial), 18 144 patients after acute coronary syndrome with low-density lipoprotein cho

292 against transfemoral access in patients with acute coronary syndrome with or without ST-segment eleva

293 The TAO trial (Treatment of Acute Coronary Syndrome With Otamixaban) randomized pati

294 itals with stable coronary artery disease or acute coronary syndromes with or without concomitant PAD

295 We randomly assigned 8404 patients with acute coronary syndrome, with or without ST-segment elev

296 ded fatal or nonfatal myocardial infarction, acute coronary syndrome without myocardial infarction, c

297 department patients with symptoms related to acute coronary syndrome without ST-elevation on ECG (n=2

298 In patients with acute coronary syndromes without ST-segment elevation, b

299 We analyzed bleeding in 12,944 patients with acute coronary syndromes without ST-segment elevation, w

300 al erosion currently causes up to a third of acute coronary syndromes; yet, we lack understanding of